| Ytd | 3.62% | |
| 1y | 5.41% |
| Open | 20.68 | Prev Close | 20.68 | Low | 20.61 | High | 20.89 | Mkt Cap | 1.53B |
| Vol | 175.96K | Avg Vol | 858.75K | EPS | 4.60 | P/E | 4.50 | Forward P/E | 9.28 |
| Beta | 0.35 | Short Ratio | 7.38 | Inst. Own | 112.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 09-08 | Earning | 08-05 | 50-d Avg | 21.99 | 200-d Avg | 21.63 | 1yr Est | 35.00 |
INVA News
Innoviva is a company that is transitioning from a pure royalty-based business to a diversified heal
Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Est
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a
Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, t
Dimensional Fund Advisors LP grew its holdings in shares of Innoviva, Inc. (NASDAQ: INVA) by 1.7% in
Nortiva Bio, Inc. (âNortivaâ) today announced its launch as a clinical-stage biopharmaceutical c
LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a cli
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Na
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc
Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements
Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Est
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "
The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's
Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day movin
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderat
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., tod
On Friday, 497 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Tuesday, 507 stocks hit new 52-week lows.
During Friday's session, 574 stocks hit new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
During Friday's morning session, 137 companies made new 52-week highs.
On Thursday morning, 159 companies achieved new highs for the year.
During Tuesday's morning trading, 101 companies set new 52-week highs.
Before 10 a.m. ET on Monday, 201 companies set new 52-week highs.
Thursday's morning session saw 167 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Monday
Benzinga's Top Upgrades, Downgrades For November 20, 2017